Product Description: C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].
Formula: C95H158F3N27O30S3
Citations: Acta Biomater. 2022 Aug 21;S1742-7061(22)00506-2./Compos B Eng. 2025 May 15.
References: [1]Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24./[2]Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680./[3]Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72.
CAS Number: 1966153-17-2
Molecular Weight: 2311.62
Compound Purity: 98.10
Research Area: Metabolic Disease; Neurological Disease; Cardiovascular Disease
Solubility: H2O : 2 mg/mL (ultrasonic)
Target: Endothelin Receptor;Histamine Receptor
English
Deutsch
